Metsera is a clinical-stage biopharmaceutical company dedicated to leading the next generation of medicines and solutions for obesity and metabolic diseases.

Founded by Population Health Partners and ARCH Venture Partners, Metsera is accelerating new medicines with potential best-in-class profiles from a proprietary library of more than 20,000 incretin and non-incretin peptides and monoclonal antibodies.

We aim to lower the disutility of first and second-generation therapies. Our planned next generation medicines, technologies and support systems are designed to make life healthier, happier, and longer.

We are a distinguished team of biopharma and consumer products and services leaders – with significant experience executing R&D and business processes at large scale.

COMPETITIVE Identify Needs & Manage Change

COMPETITIVE Develop Solutions



Board of Directors

Kristina Burow
Arch Venture Partners
Paul Berns
Arch Venture Partners
Clive Meanwell


We use only necessary cookies to ensure our website can work correctly and to enhance your experience. For more information about the cookies we use, please see our Cookie Policy.